PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Ann Rheum Dis. Author manuscript; available in PMC 2013 September 23.
Published in final edited form as:
PMCID: PMC3780983
NIHMSID: NIHMS512599

Recent insights into the genetic basis of systemic lupus erythematosus

Abstract

Many identified genetic risk factors for SLE contribute to the function of the immune system, which has expanded our understanding of disease pathogenesis. We outline the genetic variants in the recently identified SLE-associated loci, the immunologic pathways affected by these gene products, and the disease manifestations linked to these loci. Pathways potentially influenced by SLE risk variants include: apoptosis, DNA degradation and clearance of cellular debris; antigen-presentation; type I interferon, Toll-like receptor and NFκB activation; defective clearance of immune complexes containing nuclear antigens; B- and T-cell function and signaling; and monocyte and neutrophil function and signaling. These identified SLE susceptibility loci are predominantly common variants that have been confirmed among multiple ancestries, suggesting shared mechanisms in disease etiology. Ongoing genetic studies continue the investigation of specific functional variants, and their potential consequences upon immune dysregulation, enhancing our understanding of links between genotypes and specific disease manifestations. The next generation sequencing explores the identification of causal rare variants that may contribute robust genetic effects to developing SLE. Novel insights coming from genetic studies of SLE provide the opportunity to elucidate pathogenic mechanisms as well as contribute to the development of innovative therapeutic targets for this complex disease.

Keywords: Systemic lupus erythematosus, Genetic, Genome wide association studies, Interferon pathway, Cell signaling

Systemic lupus erythematosus (SLE) is a complex, autoimmune disease characterized by diverse clinical phenotypes and the presence of antibodies to nuclear components. Genetic, epigenetic, environmental and hormonal factors interact to contribute to immunologic abnormalities leading to disease pathogenesis1. The disease is variable in presentation and outcome among individuals and across ancestral groups2;3, and worldwide epidemiologic heterogeneity has been documented4. Despite this variability, a genetic basis of SLE has been established, with over 40 susceptibility loci identified at present.

Initial work exploring SLE genetics included targeted and genome-wide linkage analysis in multiplex families as well as candidate gene association studies. More recently, platforms designed to identify common variants have been used to genotype up to 0.6 million single nucleotide polymorphisms (SNPs) in each of 7 genome-wide association (GWA) studies (4 in European-derived populations, 3 in Asians), and in a series of large-scale replication studies of individuals of European, Asian and multiracial (including African-American, and Hispanics enriched in Amerindian) descent. Results from these studies have identified a growing number of novel risk loci, and confirmed disease associations with previously established risk loci. Many such loci are located either within or near genes encoding products with functional relevance to the pathogenesis of SLE, implicating the involvement of specific immune pathways. These loci thus provide an opportunity to investigate how the genetics of SLE may elucidate its pathophysiology, provide drug targets and allow for prediction of disease course.

In each GWA study, the strongest association resides within the HLA region, an extensively studied locus due to the importance of the major histocompatibility complex (MHC) to development of autoimmunity. Associations of highly conserved and extended haplotypes bearing class II alleles HLA-DRB1*03:01 and HLA-DRB1*15:015 with SLE are well-established in European populations. Recently, a high-density transancestral mapping study of the MHC region in SLE of European and Filipino ancestries identified new independent loci including MSH5 (MutS protein homolog 5) involved in DNA repair and meiotic recombination, HLA-DPB1, and HLA-G involved in maternal-fetal tolerance 6. Below, we highlight additional SLE-associated loci that have reached GWA significance after correcting for multiple testing.

Immunologic pathways affected by SLE susceptibility variants

Current understanding of SLE pathogenesis can group gene products of identified SLE-associated gene variants into pontentially influcenced mechanistic pathways, such as: (1) DNA degradation, apoptosis and clearance of cellular debris, e.g. TREX1 (three prime repair exonuclease 1), and DNASE1 (deoxyribonuclease 1); (2) defective clearance of immune complexes (ICs) containing nuclear antigens, e.g. complement components, and FCGRs (Fc fragment of IgG, low affinity receptors); (3) Toll-like receptor (TLR) and type I interferon (IFN) pathway activation, e.g. TLR7, IRF5 (interferon regulatory factor 5), and STAT4 (signal transducer and activator of transcription 4); (4) NFκB signaling, e.g. TNFAIP3 (tumor necrosis factor, alpha-induced protein 3; (5) B cell function and signaling, e.g. BANK1 (B-cell scaffold protein with ankyrin repeats 1), and BLK (B lymphoid tyrosine kinase); (6) T-cell signaling and function, e.g. PTPN22 (protein tyrosine phosphatase, non-receptor type 22), and TNFSF4 (tumor necrosis factor superfamily, member 4); and (7) monocyte and neutrophil signaling and function, e.g. ITGAM (integrin, alpha M); (see Table 1 and the text below for a description of additional genes in each pathway).

Table 1
Pathway-associated SLE candidate genes

Genetic variation in DNA degradation, apoptosis and clearance of cellular debris pathways

The proper disposal of intracellular constituents or infectious agents in a regulated manner may function inappropriately in SLE, leading to abundance of self-antigens. Several variants of genes related to these pathways contribute to both monogenic and polygenic forms of SLE. Recessive mutations typically lead to Aicardi Gutieres syndrome with deficiency of TREX1 - an exonuclease involved in cell death, DNA degradation, and cellular response to oxidative damage; deep sequencing of TREX1 identified novel frameshift or missense mutations in patients with SLE but not controls7. A large, multiethnic case-control study subsequently confirmed a TREX1 SLE risk haplotype associated with neurological manifestations in patients of European ancestry8 (see Table 2 for candidate genes and associated sub-phenotypes). Similarly, mutations of ACP5 (acid phosphatase 5, tartrate resistant), which cause spondyloenchondrodysplasia due to deficiency of TRAP (tartate-resistant acid phosphatase), a protein that functions in lysosomal digestion, lead to elevated IFN-α activity and a spectrum of autoimmune diseases including SLE 9. Rare mutations of DNASE1, encoding the major nuclease present in serum, urine and secreta and its homolog, DNASE1L3 (deoxyribonuclease 1-like 3) have been identified in several patients with SLE from homogeneous and potentially consanguineous populations10;11. Additionally, SLE-associated variants have been described in European and Asian populations of ATG5 (autophagy related 5), encoding a protein that contributes to caspase-dependent apoptosis from FAS and TNF- ligands, and degradation of cytoplasmic constituents 12.

Table 2
SLE disease phenotypes and associated candidate genes

Genetic variants of immune complex clearance and phagocytosis pathways

Defective clearance of ICs containing nuclear antigens in SLE leads to deposition in target organs. The incidence of SLE or lupus-like manifestations in individuals with a complete deficiency, due to a homozygous mutation, in one of the classical complement pathway genes ranges from 10–93% (C1Q and C1R/C1S, >90% penetrance; C4A and C4B, 75%; C2, 10–20%) 13. C1Q and C4A – which had previously been described in monogenic forms of SLE – have also been implicated in polygenic SLE and with various clinical phenotypes14. Genetic variants of CFHR1 and CFHR3 (complement factor H related genes), which may contribute to alternative complement pathway regulation among other functions, have also been associated with SLE risk in multiple ancestral groups15.

FcγR gene variants with function in IC clearance are relevant in the development of several autoimmune diseases16. The Fc receptor gene family region is complex and includes gene duplications and copy number variations, creating challenges to the investigation of gene structure. Inconsistencies between FcγRs genetic studies in SLE have been attributed to ethnic differences and disease heterogeneity, as well as genotyping error. However, the role of FcγR variants to risk of SLE is highlighted by several variants, including H131R of FCGR2A, F158V of FCGR3A, and I187T of FCGR2B, which have been associated with SLE susceptibility in several ancestral populations, and with specific disease profiles17. In addition, decreased copy numbers of FCGR3B, correlating with protein expression and IC clearance, is associated with SLE18. FcγRII and FcγRIII, the low-affinity receptors for IgG-Fc region, are important in phagocytosis, presentation of complexed antigen, and cytokine response after receptor cross-linking. The FcγRs are predominantly activating, except FcγRIIB which can inhibit signaling through other FcγRs and the B cell receptor, neutrophils and macrophages19; interestingly, a FCGRIIB functional SNP abrogates receptor function in SLE patients of both European and Southeast Asian ancestries20. Further investigation of functional consequences of the FcγR gene variants in SLE is warranted and will help to characterize their contributions to disease pathogenesis.

Genetic variants of the toll-like receptor and type I interferon pathway

Increased expression of type I IFN and type I IFN-inducible genes is observed commonly in patients with SLE, suggesting a major role in disease pathogenesis, and leading to development of anti-IFN-α therapy21. Likely candidates for triggers of type I IFN activation are binding of pattern recognition membrane and cytosolic receptors by exogenous viral agents or endogenous nucleic acids. Variants have been associated with risk of SLE; for example a functional 3′ untranslated region (UTR) SNP of the X-linked TLR7 that confers elevated TLR7 expression and an increased IFN response has been associated with SLE in East Asians22, which was subsequently confirmed in European-American, African-American and Hispanic populations23.

Variation in genes coding for transcription factors downstream of TLRs, including IRF524;25, IRF726, and IRF827;28, has been associated with SLE susceptibility. Robust associations of four IRF5 functional variants in multiple ancestries define haplotypes associated with increased, decreased, or neutral levels of risk for SLE, with functional consequences on expression of IRF5, IFN-α and IFN-inducible chemokines29. Similarly, a nonsynonymous IRF7 SNP (Q412R) confers increased IRF7 and downstream IFN pathway activation in European-, Asian-, and African-American patients with SLE 26; additional IRF7 risk alleles in patients with SLE are associated with anti-dsDNA antibodies (European-American and Hispanic-American individuals), and anti-Sm antibodies (African-American and Japanese individuals)30;31. IRF8 and susceptibility to SLE in a large multiethnic cohort was recently described28. IRF8 encodes a transcription factor that acts in the type I IFN pathway, and also plays a role in B cell and macrophage development32, however the causal variant in IRF8 has not yet been identified.

Several additional genes within or downstream of the type I IFN pathway have been associated with risk of SLE, including STAT4, IFIH1 (interferon induced with helicase C domain 1), TYK2 (tyrosine kinase 2), and PRDM1 (PR domain zinc finger protein 1)27;33. IFIH1 detects RNA prior to type I IFN pathway activation; an allele of IFIH1 was associated with anti-dsDNA antibodies among patients of multiple ancestries with SLE34. PRDM1 encodes BLIMP-1 that acts as a repressor of IFN-β gene expression, is an essential regulator of T-cell homeostasis, and may regulate both B-cell and T-cell differentiation. TYK2 interacts directly with the type I IFN receptor upon engagement with IFN-α or –β and contributes to downstream phosphorylation of STAT family and other transcription factors. STAT4, encoding a protein that promotes transcription after type I IFN receptor activation, has been associated with increased susceptibility to SLE in several ancestral backgrounds12;35;36, several sub-phenotypes and an early age of diagnosis 37;38. The genetic control of IFN activity in SLE was recently expanded to include a functional SLE risk variant in MIR146A, encoding a negative regulator of the type I IFN pathway. Decreased levels of miR-146A seen in PBMCs from Han Chinese patients with SLE may be due to decreased binding of transcription factor Ets-1 at the MIR146A promoter variant location39; genetic variation in ETS1 has also been associated with risk of SLE (see B cell section below).

Genetic variation of the NFκB pathway

Genes that play a role in the NFκB pathway downstream of TLR engagement have also been associated with increased SLE susceptibility in multiple ancestries. For example, both risk and protective haplotypes of IRAK1 (interleukin-1 receptor-associated kinase 1) have been associated with SLE40. The X-linked IRAK1 gene encodes a kinase that acts as the Myd88 complex on/off switch for activation of the NFκB inflammatory pathway. TNFAIP3, also associated with SLE and subphenotypes including renal disease41;42, encodes A20, a deubiquitinating enzyme which inhibits NFκB, leading to protein degradation and interactions that inhibit NFκB activity and TNF-mediated programmed death. A dinucleotide polymorphism just downstream of TNFAIP3 promoter region was linked to decreased expression of A20 in patients with SLE of Korean and European ancestry, and may be the risk haplotype functional variant43. TNIP1 (TNFAIP3 interacting protein 1), encoding the A20-interacting protein, has also been associated with SLE risk33;35. Additional genes within the NFκB pathway associated with SLE susceptibility include: SLC15A4 (solute carrier family 15, member 4) encoding a peptide transporter that participates in NOD1-dependent NFκB signaling35; PRKCB (protein kinase C, beta) which is involved in B-cell receptor mediated NFκB activation44; and UBE2L3 (ubiquitin-conjugating enzyme E2L 3), encoding the enzyme UBCH7 which participates in ubiquitination of an NFκB precursor, and may have a role in cell proliferation45. A risk haplotype of UBE2L3 confers increased UBCH7 expression in patients with SLE46; a variant contained in this haplotype has been associated with the presence of anti-dsDNA antibodies38.

Genetic variation of B cell signaling and function

DNA or RNA released from dying or damaged cells can be recognized by autoreactive B-cells leading to activation and production of autoantibodies that, together with additional autoantigens, form ICs that drive other proinflammatory responses. This critical role of B-cells in the development of autoimmunity has led to the development of several targeted therapies, including anti-BLyS (B lymphocyte stimulator) and anti-CD20. Several B-cell related gene variants are involved in cell signaling and have been associated with SLE susceptibility in multiple ancestral backgrounds. For example, BLK, encoding a protein functioning in intracellular signaling and regulation of proliferation, differentiation, and tolerance of B-cells35;36;47; and BANK1, whose gene product facilitates the release of intracellular calcium, altering the B-cell activation threshold36;48;49; and LYN, encoding a binding partner of BANK1 that mediates B-cell inhibition50. Three functional variants of BANK1, including R61H, A383T and rs17266594 (affecting alternative splicing) have been identified which contribute to sustained B-cell receptor signaling and B-cell hyperactivity48.

Other genes with roles in B-cell function associated with SLE susceptibility in single ancestry groups include those that encode: ETS1 (Ets-1 protein, or p54), which negatively regulates B-cell and Th17-cell differentiation49; IKZF1 (IKAROS family zinc finger 1), which regulates lymphocyte differentiation, proliferation and B-cell receptor signaling27; AFF1 (AF4/FMR2 family member 1), which functions in normal lymphocyte development51; RASGRP3 (ras guanyl-releasing protein 3) which transmits B-cell signals via Ras-ERK after B-cell receptor ligation, with potential impact on immunoglobulin production and B-cell proliferation35; IL21 which sustains antibody production, mediates antibody class switching and promotes differentiation of Th17 cells (association with SLE described in European and Hispanic ancestry)52; and IL10 which inhibits T-cells and antigen presenting cells while enhancing B-cell survival and activity33. Ongoing work from our laboratory has identified a functional SNP in the 5′ region of IL10 which is associated with higher mRNA and protein expression in SLE53.

Genetic variation of T cell signaling and function

Hyperactive B-cells, resulting from T-cell and antigen stimulation, increase the production of autoantibodies in SLE. T-cell directed therapies, including CTLA4 (cytotoxic T lymphocyte antigen 4) fusion proteins, have been developed to modulate T-cell costimulation. The production of superoxide by NADPH oxidase in leukocytes stimulated by autoantigens may be affected by an amino acid change (H389Q) in NCF2 (neutrophil cytosolic factor 2), a SLE susceptibility gene encoding a subunit of the oxidase enzyme, implicating a role for decreased reactive oxygen species in SLE pathogenesis27;54. Two genes important to T-cell signaling, R620W of PTPN22 and TNFSF4 have been associated with SLE risk55: PTPN22 is critical for T-cell signaling; TNFSF4 (or OX40L) induces co-stimulatory signals that induce activation and differentiation of B-cells and inhibit T regulatory cells. Variants of PTPN22 have been associated with both gain of function and loss of function in patients with SLE56. Additionally, CD44 encodes a cell-surface protein that regulates lymphocyte activation and apoptosis, among other functions; specific transcript isoforms in T-cells from patients with SLE suggests a role for CD44 in SLE pathogenesis57;58.

Genetic variation in monocytes and neutrophil signaling and function

Aberrant activation of monocytes and neutrophils, now recognized as important participants in SLE pathogenesis, includes the function of NETs (neutrophil extracellular traps) containing DNA and neutrophil-derived proteins which trigger for IFN-α release and can directly damage tissue21. Genetic variants related to adhesion and endothelial migration of both cell types have been associated with SLE susceptibility in multiple ancestries, specifically, R77H ITGAM and most recently the ICAM (intercellular adhesion molecule) locus12;47;59;60. ITGAM encodes the α chain of αMβ2 integrin, which regulates neutrophil and monocyte adhesion and migration from the bloodstream via interactions with a wide range of structurally unrelated ligands, including ICAM1 and ICAM2.

Ancestral Differences among SLE susceptibility genes

Most SLE-associated loci have been confirmed among multiple ancestries, suggesting common pathways play a role in disease pathogenesis. However, some susceptibility genes may be unique to particular populations: for instance, PTPN22 SLE risk alleles have been observed in European-derived but not Asian or African-American populations12;35;36, whereas loci within ETS1, WDFY4 and AFF1 have been associated with SLE only in Asian studies49;51. Variability in allelic frequency among populations explains the difference in effect of PTPN22 R620W (rs2476601; European 2–15%; Asian nearly absent) and potentially ETS1 rs1128334 (Chinese and Japanese 31–45%; European, Hispanic and African 6–11%). However, other differences in effect sizes are seen among populations, including an increased number of risk alleles for several SLE loci in Amerindian compared with European ancestry 61, and in southern Europeans compared with central Europeans62. Possible explanations for such diversity in results include: differences in allelic linkage, different gene-gene interactions, unique environmental exposures, and limitations of study design.

Genotype-phenotype effects in SLE

The diversity of clinical manifestations in SLE has generated significant interest in the potential for genetic prediction of disease sub-phenotypes. Insights into genotype effects on clinical/laboratory phenotypes have led to burgeoning understanding of the potential impact on SLE variability, and we will highlight some examples in the following paragraph. As described above, ITGAM has recently been associated with SLE in multiple ancestral groups. Upon subphenotype analysis, the ITGAM rs1143679 risk allele was found to consistently confer higher risk for lupus nephritis in SLE patients of European and Asian ancestry when compared to SLE patients without the risk allele63;64. Another robust example is that of IRF5, whereby IRF5 haplotypes determine risk for increased increased IFN-alpha activity in SLE, which is influenced by the presence of autoantibody subsets29. There may, in fact, be baseline increases in IFN activity in healthy individuals based on IRF5 haplotype, potentially leading to increased risk for development of autoantibodies and autoimmune disease65. An association of ITGAM and STAT4 also with anti-dsDNA antibody positivity in human SLE among several population groups additionally suggests the possibility of “autoantibody propensity loci” in SLE38, which may influence disease subphenotype. Cumulative evidence also points to HLA-DR2- and DR3- containing haploytpes as respectively contributing to genetic risk for presence of autoantibodies in SLE66; in a murine model, lupus-associated autoantigen proteins interact with HLA-DR3 and lead to autoreactive T cells activation, resulting in the production of autoantibodies67. Overall, however, the modest effects of most loci to date account for a small proportion of the heritability of SLE. Indeed there have been divergences in genotype-phenotype associations described by studies of different cohorts possibly due to differences in samples sizes, or a lack of complete clinical information. Learning more loci to account for heritability will enhance the link between genotype/phenotype in SLE.

Gene-gene interaction in SLE

Recent descriptions of gene-gene interactions, or epistasis, may explain some of the missing heritability in SLE. Using novel analytic tools, potential epistasis has been identified between the HLA region and CTLA4, ITGAM and IRF5, STAT4 and IRF5, PDCD1 and IL21 and between BLK and BANK1 and TNFSF4 in patients with SLE6871. These early results, whereby the presence of certain risk alleles may influence other risk alleles at different loci, suggest additional complexity to the previously accepted model of additive heritability in SLE. These results represent early stages of epistasis study in SLE; we anticipate novel insights from further analyses of functional variant interactions derived from growing numbers of susceptibility loci.

Conclusion

SLE is a complex disorder, with many new genetic associations and implications to consider in the evolving understanding of its pathogenesis. Though increasing numbers of robust associations have been identified, causal variants of many predisposing loci for SLE pathogenesis are not presently known. Functional studies will be required to determine causal variants at each locus coupled with an exploration of how identified SLE susceptibility genes contribute to disease manifestations. Ultimately specific genetic profiles may be leveraged for the prediction of risk for SLE subphenotypes and disease course at diagnosis. Currently evolving information and technology has the potential to permit significant strides towards the goal of improved medical management in SLE, and ultimately preventative care in individuals at risk for SLE.

  • The majority of large-scale genetic studies in SLE have been undertaken in European-derived, and secondly Asian, populations; focusing on other genetic backgrounds will lead to greater understanding of common pathways to autoimmunity.
  • Next generation sequencing techniques will continue to aid researchers in identifying novel rare and functional genetic variants which might account for the missing heritability in SLE.
  • Major susceptibility genes shared among multiple ancestral groups will be important in drug development for novel therapy in SLE.

Acknowledgments

Funding for this project was provided by the U.S. National Institutes of Health grants: R01AR043814 (BPT)

Footnotes

Competing Interest: None declared.

Financial disclosures: None

License for Publication

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in ARD and any other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence (http://group.bmj.com/products/journals/instructions-for-authors/licence-forms).

Reference List

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–2121. [PubMed]
2. Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus. 1999;8(3):197–209. [PubMed]
3. Alarcon GS, McGwin G, Jr, Bartolucci AA, Roseman J, Lisse J, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum. 2001;44(12):2797–2806. [PubMed]
4. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308–318. [PubMed]
5. Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 2008;4(4):e1000024. [PMC free article] [PubMed]
6. Fernando MM, Freudenberg J, Lee A, Morris DL, Boteva L, Rhodes B, et al. Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G. Ann Rheum Dis. 2012;71(5):777–784. [PMC free article] [PubMed]
7. Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007;39(9):1065–1067. [PubMed]
8. Namjou B, Kothari PH, Kelly JA, Glenn SB, Ojwang JO, Adler A, et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 2011;12(4):270–279. [PMC free article] [PubMed]
9. Briggs TA, Rice GI, Daly S, Urquhart J, Gornall H, Bader-Meunier B, et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet. 2011;43(2):127–131. [PMC free article] [PubMed]
10. Al-Mayouf SM, Sunker A, Abdwani R, Abrawi SA, Almurshedi F, Alhashmi N, et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet. 2011;43(12):1186–1188. [PubMed]
11. Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet. 2001;28(4):313–314. [PubMed]
12. Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;40(2):204–210. [PMC free article] [PubMed]
13. Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity. 2007;40(8):560–566. [PubMed]
14. Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity. 2007;40(8):560–566. [PubMed]
15. Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 2011;7(5):e1002079. [PMC free article] [PubMed]
16. Espeli M, Niederer HA, Traherne JA, Trowsdale J, Smith KG. Genetic variation, Fcgamma receptors, KIRs and infection: the evolution of autoimmunity. Curr Opin Immunol. 2010;22(6):715–722. [PubMed]
17. Li X, Ptacek TS, Brown EE, Edberg JC. Fcgamma receptors: structure, function and role as genetic risk factors in SLE. Genes Immun. 2009;10(5):380–389. [PMC free article] [PubMed]
18. Mamtani M, Anaya JM, He W, Ahuja SK. Association of copy number variation in the FCGR3B gene with risk of autoimmune diseases. Genes Immun. 2010;11(2):155–160. [PubMed]
19. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science. 2000;290(5489):84–89. [PubMed]
20. Willcocks LC, Carr EJ, Niederer HA, Rayner TF, Williams TN, Yang W, et al. A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2010;107(17):7881–7885. [PubMed]
21. Elkon KB, Stone VV. Type I interferon and systemic lupus erythematosus. J Interferon Cytokine Res. 2011;31(11):803–812. [PMC free article] [PubMed]
22. Shen N, Fu Q, Deng Y, Qian X, Zhao J, Kaufman KM, et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2010;107(36):15838–15843. [PubMed]
23. Deng Y, Zhao J, Tan WF. Association of a functional variant in TLR7 with Systemic Lupus Erythematosus and Rheumatoid Arthritis in multiple ancestries. Arthritis Rheum. 2011;63(Suppl 966) Ref Type: Abstract.
24. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet. 2005;76(3):528–537. [PubMed]
25. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet. 2006;38(5):550–555. [PubMed]
26. Fu Q, Zhao J, Qian X, Wong JL, Kaufman KM, Yu CY, et al. Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum. 2011;63(3):749–754. [PMC free article] [PubMed]
27. Cunninghame Graham DS, Morris DL, Bhangale TR, Criswell LA, Syvanen AC, Ronnblom L, et al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet. 2011;7(10):e1002341. [PMC free article] [PubMed]
28. Lessard CJ, Adrianto I, Ice JA, Wiley GB, Kelly JA, Glenn SB, et al. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet. 2012;90(4):648–660. [PubMed]
29. Niewold TB, Kelly JA, Kariuki SN, Franek BS, Kumar AA, Kaufman KM, et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis. 2012;71(3):463–468. [PMC free article] [PubMed]
30. Salloum R, Franek BS, Kariuki SN, Rhee L, Mikolaitis RA, Jolly M, et al. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum. 2010;62(2):553–561. [PMC free article] [PubMed]
31. Kawasaki A, Furukawa H, Kondo Y, Ito S, Hayashi T, Kusaoi M, et al. Association of PHRF1-IRF7 region polymorphism with clinical manifestations of systemic lupus erythematosus in a Japanese population. Lupus. 2012;21(8):890–895. [PubMed]
32. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008;26:535–584. [PubMed]
33. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet. 2009;41(11):1228–1233. [PMC free article] [PubMed]
34. Robinson T, Kariuki SN, Franek BS, Kumabe M, Kumar AA, Badaracco M, et al. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-alpha and serologic autoimmunity in lupus patients. J Immunol. 2011;187(3):1298–1303. [PMC free article] [PubMed]
35. Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet. 2009;41(11):1234–1237. [PubMed]
36. Sanchez E, Comeau ME, Freedman BI, Kelly JA, Kaufman KM, Langefeld CD, et al. Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. Arthritis Rheum. 2011;63(11):3493–3501. [PMC free article] [PubMed]
37. Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet. 2008;4(5):e1000084. [PMC free article] [PubMed]
38. Chung SA, Taylor KE, Graham RR, Nititham J, Lee AT, Ortmann WA, et al. Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. PLoS Genet. 2011;7(3):e1001323. [PMC free article] [PubMed]
39. Luo X, Yang W, Ye DQ, Cui H, Zhang Y, Hirankarn N, et al. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet. 2011;7(6):e1002128. [PMC free article] [PubMed]
40. Jacob CO, Zhu J, Armstrong DL, Yan M, Han J, Zhou XJ, et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2009;106(15):6256–6261. [PubMed]
41. Bates JS, Lessard CJ, Leon JM, Nguyen T, Battiest LJ, Rodgers J, et al. Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations. Genes Immun. 2009;10(5):470–477. [PMC free article] [PubMed]
42. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon JM, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet. 2008;40(9):1059–1061. [PMC free article] [PubMed]
43. Adrianto I, Wen F, Templeton A, Wiley G, King JB, Lessard CJ, et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet. 2011;43(3):253–258. [PMC free article] [PubMed]
44. Sheng YJ, Gao JP, Li J, Han JW, Xu Q, Hu WL, et al. Follow-up study identifies two novel susceptibility loci PRKCB and 8p11. 21 for systemic lupus erythematosus. Rheumatology (Oxford) 2011;50(4):682–688. [PubMed]
45. Budarf ML, Goyette P, Boucher G, Lian J, Graham RR, Claudio JO, et al. A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles. Genes Immun. 2011;12(1):51–58. [PubMed]
46. Wang S, Adrianto I, Wiley GB, Lessard CJ, Kelly JA, Adler AJ, et al. A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. Genes Immun. 2012 [PMC free article] [PubMed]
47. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med. 2008;358(9):900–909. [PubMed]
48. Kozyrev SV, Abelson AK, Wojcik J, Zaghlool A, Linga Reddy MV, Sanchez E, et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet. 2008;40(2):211–216. [PubMed]
49. Yang W, Shen N, Ye DQ, Liu Q, Zhang Y, Qian XX, et al. Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet. 2010;6(2):e1000841. [PMC free article] [PubMed]
50. Lu R, Vidal GS, Kelly JA, Delgado-Vega AM, Howard XK, Macwana SR, et al. Genetic associations of LYN with systemic lupus erythematosus. Genes Immun. 2009;10(5):397–403. [PMC free article] [PubMed]
51. Okada Y, Shimane K, Kochi Y, Tahira T, Suzuki A, Higasa K, et al. A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus eyrthematosus in Japanese. PLoS Genet. 2012;8(1):e1002455. [PMC free article] [PubMed]
52. Webb R, Merrill JT, Kelly JA, Sestak A, Kaufman KM, Langefeld CD, et al. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum. 2009;60(8):2402–2407. [PMC free article] [PubMed]
53. Sakurai D, Zhao J, Yeal Deng. Risk Alleles of SLE Associated IL10 SNPs Conferred Differential Binding to Transcription Factors. Arthritis Rheum. 63(Suppl 966):2011. Ref Type: Abstract.
54. Jacob CO, Eisenstein M, Dinauer MC, Ming W, Liu Q, John S, et al. Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase. Proc Natl Acad Sci U S A. 2012;109(2):E59–E67. [PubMed]
55. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004;75(3):504–507. [PubMed]
56. Orru V, Tsai SJ, Rueda B, Fiorillo E, Stanford SM, Dasgupta J, et al. A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet. 2009;18(3):569–579. [PMC free article] [PubMed]
57. Crispin JC, Keenan BT, Finnell MD, Bermas BL, Schur P, Massarotti E, et al. Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum. 2010;62(5):1431–1437. [PMC free article] [PubMed]
58. Lessard CJ, Adrianto I, Kelly JA, Kaufman KM, Grundahl KM, Adler A, et al. Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. Am J Hum Genet. 2011;88(1):83–91. [PubMed]
59. Kim K, Brown EE, Choi CB, Alarcon-Riquelme ME, Kelly JA, Glenn SB, et al. Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries. Ann Rheum Dis. 2012 [PMC free article] [PubMed]
60. Nath SK, Han S, Kim-Howard X, Kelly JA, Viswanathan P, Gilkeson GS, et al. A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet. 2008;40(2):152–154. [PubMed]
61. Sanchez E, Webb RD, Rasmussen A, Kelly JA, Riba L, Kaufman KM, et al. Genetically determined Amerindian ancestry correlates with increased frequency of risk alleles for systemic lupus erythematosus. Arthritis Rheum. 2010;62(12):3722–3729. [PMC free article] [PubMed]
62. Alonso-Perez E, Suarez-Gestal M, Calaza M, Sebastiani GD, Pullmann R, Papasteriades C, et al. Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: a case-control study. Arthritis Res Ther. 2012;14(2):R94. [PMC free article] [PubMed]
63. Kim-Howard X, Maiti AK, Anaya JM, Bruner GR, Brown E, Merrill JT, et al. ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Ann Rheum Dis. 2010;69(7):1329–1332. [PMC free article] [PubMed]
64. Yang W, Zhao M, Hirankarn N, Lau CS, Mok CC, Chan TM, et al. ITGAM is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai. Hum Mol Genet. 2009;18(11):2063–2070. [PMC free article] [PubMed]
65. Rullo OJ, Woo JM, Wu H, Hoftman AD, Maranian P, Brahn BA, et al. Association of IRF5 polymorphisms with activation of the interferon alpha pathway. Ann Rheum Dis. 2010;69(3):611–617. [PMC free article] [PubMed]
66. Graham RR, Ortmann W, Rodine P, Espe K, Langefeld C, Lange E, et al. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur J Hum Genet. 2007;15(8):823–830. [PubMed]
67. Deshmukh US, Sim DL, Dai C, Kannapell CJ, Gaskin F, Rajagopalan G, et al. HLA-DR3 restricted T cell epitope mimicry in induction of autoimmune response to lupus-associated antigen SmD. J Autoimmun. 2011;37(3):254–262. [PMC free article] [PubMed]
68. Abelson AK, Delgado-Vega AM, Kozyrev SV, Sanchez E, Velazquez-Cruz R, Eriksson N, et al. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis. 2009;68(11):1746–1753. [PubMed]
69. Castillejo-Lopez C, Delgado-Vega AM, Wojcik J, Kozyrev SV, Thavathiru E, Wu YY, et al. Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK. Ann Rheum Dis. 2012;71(1):136–142. [PMC free article] [PubMed]
70. Hughes T, Adler A, Kelly JA, Kaufman KM, Williams AH, Langefeld CD, et al. Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. Arthritis Rheum. 2012;64(2):485–492. [PMC free article] [PubMed]
71. Zhou XJ, Lu XL, Nath SK, Lv JC, Zhu SN, Yang HZ, et al. Gene-gene interaction of BLK, TNFSF4, TRAF1, TNFAIP3, and REL in systemic lupus erythematosus. Arthritis Rheum. 2012;64(1):222–231. [PubMed]
72. He CF, Liu YS, Cheng YL, Gao JP, Pan TM, Han JW, et al. TNIP1, SLC15A4, ETS1, RasGRP3 and IKZF1 are associated with clinical features of systemic lupus erythematosus in a Chinese Han population. Lupus. 2010;19(10):1181–1186. [PubMed]
73. Ramantani G, Kohlhase J, Hertzberg C, Innes AM, Engel K, Hunger S, et al. Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutieres syndrome. Arthritis Rheum. 2010;62(5):1469–1477. [PubMed]
74. Briggs TA, Rice GI, Daly S, Urquhart J, Gornall H, Bader-Meunier B, et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet. 2011;43(2):127–131. [PMC free article] [PubMed]
75. Niewold TB, Kelly JA, Kariuki SN, Franek BS, Kumar AA, Kaufman KM, et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis. 2012;71(3):463–468. [PMC free article] [PubMed]
76. Schotte H, Gaubitz M, Willeke P, Tidow N, Assmann G, Domschke W, et al. Interleukin-10 promoter microsatellite polymorphisms in systemic lupus erythematosus: association with the anti-Sm immune response. Rheumatology (Oxford) 2004;43(11):1357–1363. [PubMed]
77. Capper ER, Maskill JK, Gordon C, Blakemore AI. Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology? Clin Exp Immunol. 2004;138(2):348–356. [PubMed]
78. Yin H, Borghi MO, Delgado-Vega AM, Tincani A, Meroni PL, Alarcon-Riquelme ME. Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum. 2009;60(8):2468–2471. [PubMed]
79. Sanchez E, Nadig A, Richardson BC, Freedman BI, Kaufman KM, Kelly JA, et al. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis. 2011;70(10):1752–1757. [PMC free article] [PubMed]
80. Roumenina LT, Sene D, Radanova M, Blouin J, Halbwachs-Mecarelli L, Dragon-Durey MA, et al. Functional complement C1q abnormality leads to impaired immune complexes and apoptotic cell clearance. J Immunol. 2011;187(8):4369–4373. [PubMed]
81. Alarcon GS, McGwin G, Jr, Petri M, Ramsey-Goldman R, Fessler BJ, Vila LM, et al. Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med. 2006;3(10):e396. [PMC free article] [PubMed]
82. Zhu LJ, Liu ZH, Zeng CH, Chen ZH, Yu C, Li LS. Association of interleukin-10 gene -592 A/C polymorphism with the clinical and pathological diversity of lupus nephritis. Clin Exp Rheumatol. 2005;23(6):854–860. [PubMed]
83. Kaufman KM, Rankin J, Harley IT, Kelly JA, Harley JB, Scofield RH. A genetic marker within the CD44 gene confirms linkage at 11p13 in African-American families with lupus stratified by thrombocytopenia, but genetic association with CD44 is not present. Genes Immun. 2002;3 (Suppl 1):S86–S88. [PubMed]